AT1 FY21 - General Discussion + FA, page-357

Posting some interesting AccBio info here as the other Ag test agreement thread is a month old already...

22 Nov'20 - Ginkgo Bioworks Funds Expansion of Rapid Antigen Test Manufacturing with Access Bio in New Jersey
_{https://synbiobeta.com/ginkgo-bioworks-funds-expansion-of-rapid-antigen-test-manufacturing-with-access-bio-in-new-jersey/}
- AccBio signed contract with Ginkgo to supply 10m Ag RDTs + receive additional capital to expand Ag RDT manufacturing (for an undisclosed contract conditions + amount but I believe this was secured via new convertible notes; see below)

20 Nov'20 - Accbio KRX disclosure for US$7m+ expenditure for "purchase of automated production equipment to expand production capacity of corona diagnostic kits"_{http://dart.fss.or.kr/dsaf001/main.do?rcpNo=20201120900057}

18 Nov'20 - AccBio KRX disclosure for US$10m convertible bonds being issued (~414k shares based on mkt price)
_{http://dart.fss.or.kr/dsaf001/main.do?rcpNo=20201118900080}

Btw Ginkgo Bioworks is one of the world's largest privately held biotech companies (US$4.2b valuation)
_{https://en.wikipedia.org/wiki/Ginkgo_Bioworks
https://www.ginkgobioworks.com/}

And Ginkgo plans to collaborate with AccBio on future RDTs that leverage Ginkgo's synthetic biology technology to improve antibodies
_{https://www.360dx.com/business-news/ginkgo-bioworks-collaborating-access-bio-covid-19-antigen-tests#.X7uic2gzaUk}

And separately:
20 Nov'20 - AccBio KRX disclosure for US$4.2m worth Ag RDTs purchase order by their US distro (Intrivo Diagnostics)
http://dart.fss.or.kr/dsaf001/main.do?rcpNo=20201120900049

Though none of this is directly relevant to AT1 or financially we gain anything (yet), I have a couple assumptions/hopeful thoughts:

- AT1's second largest partner is doing quite well + its further investing in Ag RDT manufacturing ability, which means zero supply problems if AT1's requires large orders for markets like India (hopefully, right?)

- it is a solid market potential indicator that these companies expect to continue providing Covid19 related testing for the foreseeable future; seeing the size of investment $ still being thrown at this

- AccBio has the existing manufacturing licence for Pascal devices; which we saw in a previous KRX disclosure seems to be connected to new AccBio HIV RDT; there is also a possibility of 'new' future tests/markets being developed using Ginkgo organism tech + AccBio test strips + AT1 devices.